



(Translation)

Minutes of the 2026 Annual General Meeting of Shareholders  
Ratchaphruek Hospital Public Company Limited

**Date, Time, and Venue**

The 2026 Annual General Meeting of Shareholders of Ratchaphruek Hospital Public Company Limited (the “Company”) was held on Wednesday April 22, 2026, at 13.00 hours, **The meeting was held electronically (e-meeting) only** and livestreamed from Ratchaphruek Hospital Public Company Limited, 456 Mittraparb Road, Nai-Mueang Sub-district, Mueang District, Khon Kaen.

**Quorum**

As of the record date for determining the shareholders entitled to attend the Annual General Meeting, the Company had a total paid-up registered capital of Baht 546,000,000, divided into 546,000,000 ordinary shares with a par value of Baht 1 per share. For the purpose of determining the quorum and voting rights, the Company is required to exclude treasury shares repurchased under the share repurchase program totaling 15,593,000 shares, representing 2.86% of the total issued shares, as such treasury shares shall not be counted toward the quorum, shall have no voting rights, and shall not be entitled to dividend payments. Accordingly, the total number of shares entitled to vote at the Meeting was 530,398,500 shares.

At the commencement of the Meeting, there were 44 shareholders and proxies attending the Meeting, representing a total of 227,149,965 shares, or 42.8263% of the total voting shares. The quorum was therefore duly constituted in accordance with applicable laws and the Company’s Articles of Association, which require that at least 25 shareholders or not less than one-half of the total number of shareholders attend the Meeting, either in person or by proxy, and that the total number of shares held by those attending must not be less than one-third of the total issued shares of the Company.

Miss Chularat Sirisingh, Company Secretary and Investor Relations, acting as the Meeting Moderator (“Moderator”), welcomed the shareholders and proxies of Ratchaphruek Hospital Public Company Limited (the “Company”) to the 2026 Annual General Meeting of Shareholders and proceeded to introduce the Directors and Management members present at the Meeting as follows:

**Directors attending the Meeting:**

- |  |  |
|--|--|
| 1. Mr.Sudhon Sriyapant                         | Chairman of the Board of Directors   |
| 2. Professor Dr. Vallop Laiboom, M.D.          | Vice Chairman <i>(via livestream)</i>  |
| 3. Dr.Teerawt Srinakarin, M.D.                 | Director and Chief Executive Offer <i>(at livestreamed)</i>  |
| 4. Associate Professor Dr.Srichai Krusun, M.D. | Director <i>(at livestreamed)</i>  |
| 5. Professor Clinic Dr.Suphan Srithamma, M.D.  | Director and Chairman of Risk Management Committee <i>(via electronic)</i>   |
| 6. Mr.Vairoj Jindamaneepitak                   | Independent Director, Chairman of the Audit Committee<br>Member of Risk Management Committee <i>(via electronic)</i> |
| 7. Mr.Vorathep Rangchaikul                     | Independent Director, Member of the Audit Committee <i>(via electronic)</i>  |
| 8. Miss Orawan Sirirattanawong                 | Independent Director, Member of the Audit Committee <i>(via electronic)</i>  |
| 9. Dr.Sirikul Laukaikul                        | Independent Director <i>(via electronic)</i>   |
| 10. Mrs.Tina Chiarasiri                        | Independent Director,<br>Member of Risk Management Committee <i>(via electronic)</i>                                 |



(There were 10 out of 10 directors attending the meeting, representing 100% of total directors.)

**The Management attending the Meeting (at livestreamed) :**

- |   |   |
|---|---|
| 1. Miss Chularat Sirisingh                          | Company Secretary (CS) / Moderator and minute taker |
| 2. Miss Supaporn Sukhee                             | Chief Financial Officer (CFO)                       |
| 3. Miss Airin Ngam-Sombutcharoen                    | Deputy Chief Financial Officer (DCFO)               |
| 4. Associate Professor Dr.Jiraporn Srinakarin, M.D. | Chief Medical Officer (CMO)                         |

**The Company Auditor from PV Audit Limited**

- |                          |                             |
|--------------------------|-----------------------------|
| 1. Mr.Boonkasen Sarnklin | Certified Public Accountant |
|--------------------------|-----------------------------|

**Attending Representative who protects the rights of shareholders, from Thai Investors Association**

- |                               |
|-------------------------------|
| 1. Miss Chanathip Wittayakoon |
|-------------------------------|

**Meeting commenced**

The Moderator informed the Meeting that the convening of this Meeting was in accordance with the resolution of the Board of Directors' Meeting No. 2/2026, held on 14 February 2026. The purpose of the Meeting is to consider various matters as set out in the Notice of the Meeting, which had been duly delivered to all shareholders.

The Company has fixed 13 March 2026 as the record date for determining the shareholders entitled to attend the 2026 Annual General Meeting of Shareholders.

In addition, the Company has announced its Personal Data Protection Policy for the 2026 Annual General Meeting of Shareholders in compliance with the Personal Data Protection Act B.E. 2562 (2019). The relevant criteria and guidelines have been provided to all shareholders together with the Notice of the Meeting on pages 1–2. Shareholders may also review further details on the Company's website.

For this Meeting, the Company has arranged for video recording of the proceedings, and the recorded video will be published on the Company's website.

The Moderator then explained the criteria and procedures for voting on each agenda item, which were presented via a video presentation, with details as follows:

**Agenda Meeting**

The meeting agenda consists of 7 items to consider other matters in addition to those specified in the meeting invitation letter.

Agenda 1 To acknowledge the Company and subsidiary operational results for the year 2025

Agenda 2 To approve the Audit financial statements for the fiscal year ended December 31, 2025

Agenda 3 To approve the legal reserve and annual dividend payment for the year ended December 31, 2025

Agenda 4 To approve the election of directors to replace the directors retiring by rotation for the year 2026

Agenda 5 To consider the determination of remuneration of the Board of Directors and subcommittee for the year 2026

Agenda 6 To consider and approve the Appointment of Auditors and Determination the Audit Fee for the year 2026

Agenda 7 Other matters (if any)



## Criteria and methods for voting

1. Each shareholder shall have one vote per share (1 share = 1 vote). Shareholders who have a special interest in any matter shall not be entitled to vote on such matter.
2. The electronic meeting system used by the Company is provided by an independent external service provider, namely Online Asset Co., Ltd., which operates the meeting control system in accordance with the standards of the Electronic Transactions Development Agency (ETDA) ("IR PLUS AGM"). This system facilitates shareholders' participation from any location, provides access to meeting documents and presentation materials in various media formats, enables voting on each agenda item, and allows shareholders to submit questions or express opinions throughout the Meeting via text. Voting procedures shall remain in compliance with applicable laws and regulations.
3. The Meeting will consider the agenda items in the order as specified in the Notice of the Meeting. Shareholders will be given the opportunity to raise questions or express opinions relevant to each agenda item, as appropriate, prior to voting. The voting results for each agenda item will be announced to the Meeting upon completion of vote counting.
4. Shareholders may cast their votes on each agenda item via the IR PLUS AGM system by selecting "Approve," "Disapprove," or "Abstain." If a shareholder does not select any option for a particular agenda item, the system will deem that the shareholder has voted "Approve" for that item. As voting is conducted through an online application, there will be no invalid ballots, except for proxy forms submitted to the Company in advance, which shall be considered invalid in the following cases:
  - (1) Voting marked in more than one box, except in the case of a custodian;
  - (2) Voting that expresses conflicting intentions, except in the case of a custodian.
5. For shareholders who have appointed a director or an independent director as their proxy, the Company will cast votes in accordance with the shareholders' instructions as specified in the proxy forms.
6. Shareholders will be given one (1) minute to cast their votes for each agenda item. Once the online voting is closed, the votes cannot be changed.

## The calculation methods of the base for vote counting are as follows:

1. Any agenda requires the base of votes to be calculated from the shareholders attending the meeting and voting shall count the number of shareholders attending the meeting and voting, any "abstained" vote will be excluded from the base of votes.
2. Any agenda requiring the base of votes to be calculated as the total number of shareholders attending the meeting and voting shall count a total number of shareholders attending the meeting and having voting rights, any "abstained" vote will be included into the base of votes.
3. If a shareholder exits the system during the meeting, their votes for that agenda item will be removed from the calculation, in accordance with the announcement of the Ministry of Digital Economy and Society regarding the standards of electronic meeting security (B.E. 2563).

However, this does not revoke their right to vote in future agenda items. Shareholders may re-enter the system and join the meeting at any time until the meeting is officially closed.



## Vote Counting Method

- For the 2026 Annual General Shareholders' Meeting, the agenda items are divided into two parts:  
**Part1:** Agenda items requiring a majority vote of shareholders present and eligible to vote items 2, 3, 4, and 6.  
**Part2:** Agenda item 5, regarding directors' remuneration, which requires approval by two-thirds of shareholders present and voting.
- For the 2026 director election agenda, shareholders are asked to vote for each director individually through the system.

## Procedures for Asking Questions or Expressing Opinions

- Prior to voting on each agenda item, the Company will provide an opportunity for shareholders or proxies to ask questions or express opinions relevant to such agenda item, as appropriate.
- Shareholders or proxies who wish to ask questions or express opinions may submit their questions through the system or via the IR Plus AGM platform. In the case of asking questions verbally, shareholders are requested to turn on their camera and microphone upon being invited to speak, and to state their full name before asking any question.
- For questions or comments during the Meeting, prior to voting on each agenda item, participants may select the agenda item for which they wish to ask questions or express opinions and click the “Question” button. This can be done through two channels as follows:
- Text-base inquiries:  
Participants may click the menu icon located at the bottom right of the screen, which is available for all agenda items, then type their questions and click “Submit.” The Company will read and respond to questions relevant to the agenda item to the Meeting. However, if there are numerous questions submitted, the Company reserves the right to consider and select questions as appropriate.
- Video call inquiries:  
Participants may click the menu icon located at the top right of the screen, which is available for all agenda items, then type a preliminary question and wait for a response from the staff. The Moderator will announce the name of the participant who is granted the opportunity to speak. Upon receiving the signal, the participant is requested to turn on their camera and microphone and to be properly attired.
- The Company reserves the right to terminate the audio and video of any participant who uses inappropriate language, defames others, violates the law, infringes upon the rights of others, or behaves in a manner that disrupts the Meeting or causes inconvenience to other participants.
- In the event that there are a large number of shareholders wishing to ask questions via video call, in order to ensure the Meeting proceeds efficiently within the allocated time, the Company kindly requests that shareholders primarily submit questions via text. The staff will respond to such questions or address them at the end of the Meeting. The Company will summarize all questions and answers as an appendix to the



minutes of the shareholders' meeting and disclose them through the Stock Exchange of Thailand's information dissemination system and the Company's website within 14 days from the date of the Meeting.

#### **In the event that shareholders encounter difficulties accessing the Meeting system or the voting system**

1. In case shareholders experience difficulties in using the Meeting system or voting system, they are advised to review and follow the instructions provided together with the Notice of the Meeting. Alternatively, shareholders may contact the IR PLUS AGM support staff via the telephone number and Line Official account displayed on the screen.
2. The Company has provided an E-Proxy Voting system for shareholders who wish to appoint proxies electronically. Individual shareholders who are members of the Investor Portal (IVP) and have completed identity verification via the National Digital ID (NDID) system may use the service through the Investor Portal (IVP). Meanwhile, mutual funds managed by asset management companies and foreign juristic persons under custodianship may use the e-Proxy Voting for Intermediaries system.
3. The Moderator further informed the Meeting that, during the Meeting, if any shareholder or proxy encounters technical issues or has inquiries regarding the Meeting system, they may contact the Call Center via the telephone number provided in the Notice of the Meeting or as displayed on the screen at any time until the Meeting is concluded.

After the shareholders acknowledged and raised no objections to the voting procedures, vote counting, announcement of voting results, and procedures for asking questions as described above, the Moderator stated that:

The Company has complied with the principles of good corporate governance by providing shareholders with the opportunity to propose agenda items in advance. Such opportunity was publicly announced via the Company's website and the Stock Exchange of Thailand's website during the period from 1 October to 31 December 2025. Upon the expiration of the specified period, no shareholders proposed any agenda items for the Board's consideration.

Accordingly, the agenda for the 2026 Annual General Meeting of Shareholders has been determined based on the items required by law. The Meeting will proceed strictly in accordance with the agenda items as specified in the Notice of the Meeting, without rearrangement or addition of any new agenda items.

Thereafter, Mr. Sudhon Sriyapan, Chairman of the Board, was invited to preside over the Meeting in accordance with Article 34 of the Company's Articles of Association and to proceed with the Meeting agenda. The Chairman reported the attendance of shareholders as follows:

- Shareholders attending in person: 9 persons, representing 124,335,750 shares
- Proxies: 51 persons, representing 96,894,365 shares
- Shareholders attending online: 2 persons, representing 95,990 shares
- Proxies attending online: 2 persons, representing 5,823,860 shares
- Total: 64 persons, representing 227,149,965 shares
- Equivalent to 42.8263% of the total issued and paid-up shares of 530,398,500 shares



The Chairman also assigned Professor Vallop Laopaiboon, Vice Chairman of the Board, to act as co-moderator for each agenda item together with the Meeting Moderator.

### Agenda Item 1: Acknowledgement of the Company's and Subsidiaries' 2025 Performance

Professor Vallop Laopaiboon, Vice Chairman of the Board explained that, in accordance with the Public Limited Companies Act B.E. 2535 and the company's regulations, the board must report performance to the shareholders in the annual general meeting.

Dr. Teerawat Srinakarin, Director and CEO, was assigned to present the performance summary and significant changes for the fiscal year ending December 31, 2025, as detailed in the 2025 Annual Report (Form 56-1 e-One Report).

#### Agenda 1: Key Financial Performance for 2025

The Company reported its financial performance for 2025, demonstrating continued growth. Revenue from core operations, primarily derived from general medical services, increased by 5.57% year-on-year.

In addition to revenue growth, the Company improved profitability across all key metrics, as follows:

- Net Profit Margin increased to 15.35%
- EBITDA Margin increased to 26.17%
- Return on Equity (ROE) improved to 10.49%

Revenue structure is categorized into Outpatient (OPD) and Inpatient (IPD) services as follows:

#### Outpatient (OPD)

Revenue increased slightly by 1.65%. While patient volume grew modestly and utilization declined during certain periods, revenue per visit increased, reflecting higher treatment value. The proportion of OPD revenue remained stable at 39.10% of total revenue.

#### Inpatient (IPD)

Revenue increased by 4.34%, despite a decline in patient numbers and length of stay. Bed occupancy rate improved to 64.89%. IPD remains the core revenue driver, accounting for approximately 60.90% of total operating revenue. Growth was primarily driven by higher revenue per case, particularly from endoscopic procedures and gastrointestinal treatments.

#### Revenue Mix by Patient Segment

The proportion of self-pay patients decreased to 49.39% from 51.17%, reflecting economic conditions. Meanwhile, insured and contracted patients increased to 45.27% from 42.79%. Combined, these two groups accounted for over 94% of total revenue, indicating a strong and low credit-risk patient base.

Overall, the Company achieved high-quality growth in both revenue and profitability, driven by value-based healthcare and effective revenue structure management.

### Agenda 2: International Hospital Accreditation Progress

The Company reported progress in elevating organizational standards.

As a member of Planetree International, the Company has successfully achieved the Gold Standard certification, the highest level. The formal on-site assessment remains under consideration, as the Company balances resource allocation and cost management with other strategic initiatives.

The Company focuses on three key development areas:

1. Patient Experience – Enhancing service quality across all patient touchpoints
2. People Development – Strengthening capabilities of medical staff and employees at all levels



### 3. Healing Process – Emphasizing safety, patient experience, and Humanized Patient-Centered Care

Additionally, the Company continues to strengthen its Risk Culture to ensure high standards of safety and long-term sustainability.

#### Awards in 2025

The Company received the Carbon Footprint for Organization (CFO) certification from the Thailand Greenhouse Gas Management Organization (TGO), covering Scope 1 and 2 emissions totaling 2,880 tCO<sub>2</sub>e/year, verified by BSI Group (Thailand) Co., Ltd., and officially registered on 18 March 2026.

#### Agenda 3: Corporate Governance (CG) Performance

##### 1. The Company achieved strong CG performance in 2025:

- CGR Rating: Excellent (4 stars)
- AGM Checklist Score: 100 points

##### 2. Board Composition and Diversity

The Company maintains a diverse Board, including gender diversity. Currently, 3 female directors (30%) serve as independent directors.

##### 3. Policy Review

- Annual review of vision, mission, and strategy
- Policy limiting directorship in listed companies to no more than 5
- Dividend policy established for the Company and subsidiaries

##### 4. Anti-Corruption and Governance

The Company continues to strengthen transparency through:

- Reduced cash transactions
- Anti-corruption policy review and training workshops
- Whistleblowing channels via the Company website

##### 5. Performance (2023–2025)

- No corruption or fraud cases
- No financial misconduct complaints
- No CG violations
- No ESG-related disputes or litigation

The Company maintains strong internal controls and provides multi-level whistleblowing channels, including direct reporting to the Audit Committee Chairman and Chairman of the Board.

Key initiatives include:

- No Gift Policy Campaign
- “Speak & Relief” program – anonymous reporting channel for employees

#### Agenda 4: Environmental and Sustainability

The Company has integrated environmental impact management into its business operations in order to promote efficient resource utilization, minimize environmental impact, and support sustainable development. As a result, the Company has achieved tangible reductions in resource consumption costs. In addition, the Company’s environmental data has been externally verified in connection with the Carbon Footprint for Organization (CFO) certification by a verifier registered with the Thailand Greenhouse Gas Management Organization (TGO).



Furthermore, the Company actively promotes environmental initiatives within the hospital by encouraging personnel to participate in proposing ideas and innovations, such as waste segregation, waste reduction, efficient use of resources, and energy conservation. These efforts reflect the Company’s commitment to fostering an environmental culture aligned with the Green Hospital concept and ESG framework.

In terms of safety, the Company regularly conducts training and emergency preparedness drills to enhance staff readiness in responding to emergency situations accurately, promptly, and effectively. These include drills for earthquake scenarios, violent incidents, mass casualty events, infant or child abduction, and fall-risk situations. Such activities demonstrate the Company’s continuous commitment to risk management and maintaining high safety standards.

On the social dimension, the Company organizes health education activities for the public through training programs, seminars, and medical outreach initiatives. It also supports educational development for both the public and its personnel, contributing to the enhancement of knowledge and quality of life in the surrounding community.

At the same time, as a listed company, the Company places strong emphasis on transparent communication with investors. The Company participates in activities such as Opportunity Day and continuously communicates through various channels to disclose its performance and business direction to shareholders, investors, and stakeholders appropriately.

The Company believes that its efforts across all these dimensions form a solid foundation for sustainable, transparent, and long-term growth, while strengthening confidence among shareholders, investors, patients, employees, and all stakeholders.

#### **Agenda 5: Progress of Rajapruek–Kaenphanga Hospital**

The Chairman of Kaenphanga Co., Ltd. reported that the new hospital project, “Rajapruek–Kaenphanga Hospital,” is under development.

Construction is progressing as planned, with expected completion and opening within 2026, targeted for 11 November 2026.

The construction progress is in line with the planned schedule. As of the second quarter of 2026, the project is ongoing as expected and is anticipated to commence operations within 2026, with a targeted opening date of 11 November 2026.

Regarding the design concept, the hospital emphasizes a Healing Environment and Humanized Person-Centered Care to enhance patient experience. Key considerations include ambiance, cleanliness, safety, as well as air quality control systems and infection prevention measures in critical areas of the hospital.

The hospital will comprise 2 major operating rooms, 6 minor operating rooms, and 20 inpatient beds. The facilities are designed to create a warm, comfortable, and nature-connected environment to support patient recovery and build confidence among service recipients.

Furthermore, Ratchaphruek–Kaenphanga Hospital will operate under three core principles: Beauty, Truth, and Goodness. The hospital aims to provide aesthetic and plastic surgery services that integrate the art of beauty with medical science, safety, and professional ethics, thereby creating differentiation and building trust among patients. This is reflected in the concepts “Beauty without Risk” and “Awaken Your Beauty,” while positioning its services as Accessible Premium, offering premium-quality care that remains accessible.



After the allotted time for questions had elapsed, no questions were submitted by any shareholders or proxies.

The Chairman then proceeded to the next agenda item.

**Resolution:** As this agenda item was for acknowledgment, no voting was required.

*Note:* During this agenda item, an additional 5 shareholders joined the Meeting, representing 2,442,100 shares. The total number of attendees increased to 69 persons, representing a total of 229,592,065 shares.

## Agenda 2 To approve the Audit financial statements for the fiscal year ended December 31, 2025

The Chairman assigned Miss Airin Ngam-sombutcharoen, Deputy Chief Financial Officer (DCFO), to report the financial statements for the year ended December 31, 2025, for the consideration of the Meeting, which could be.

Pursuant to Section 112 of the Public Limited Companies Act B.E. 2535 (1992) and Article 39 of the Company's Articles of Association, the Company is required to prepare its Statement of Financial Position and Statement of Comprehensive Income as of the end of the Company's accounting period for submission to the Annual General Meeting of Shareholders for approval.

The Audit Committee and the Board of Directors have reviewed the financial statements, together with the auditor's report, and are of the opinion that such financial statements have been prepared in accordance with the Financial Reporting Standards and that adequate disclosure of material information has been made.

The auditor has expressed an unqualified opinion, stating that the financial statements present fairly, in all material respects, the financial position of the Company as 31 December 2025, as well as its financial performance and cash flows for the year then ended, in accordance with the applicable financial reporting standards.

The key highlights of the Statement of Financial Position and the Statement of Comprehensive Income for the year ended 31 December 2025 are summarized as follows:

### The statements of financial position and income statements

items	Consolidated financial statements (Unit: million Baht)		Change (percent)
	2025	2024	
Cash and cash equivalents	280.18	291.49	(3.88%)
Trade and other receivables	107.33	90.57	18.51%
Inventories	26.39	24.16	9.24%
Other current financial assets	100.30	150.30	(33.27%)
Property, plant and equipment	1,313.28	1,321.42	(0.62%)
Other non-current assets	81.02	50.24	61.27%
<b>TOTAL ASSETS</b>	<b>1,908.50</b>	<b>1,928.18</b>	<b>(1.02%)</b>
Total Liabilities	193.07	165.89	16.38%
Total Shareholders' Equity	1,715.43	1,762.29	(2.66%)
<b>TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY</b>	<b>1,908.50</b>	<b>1,928.18</b>	<b>(1.02%)</b>



## Analysis of financial position as of 31 December 2025 and 31 December 2024

### Total Assets

As of 31 December 2025, the Company had total assets of Baht 1,908.50 million, representing a decrease of 1.02% from the end of 2024. The decline was primarily attributable to a reduction in cash and cash equivalents, resulting from dividend payments and the Company's share repurchase program.

Property, plant and equipment amounted to Baht 1,313.28 million, decreasing by 0.62% due to normal depreciation. Meanwhile, other non-current assets increased significantly by 61.27%, mainly due to advance payments made by a subsidiary for a construction project.

Other non-current assets decreased due to the recognition of amortization for right-of-use assets and intangible assets as part of normal operations. Additionally, right-of-use assets that reached the end of their lease terms were reclassified as property, plant, and equipment, net.

### Total Liabilities

As of 31 December 2025, the Company had total liabilities of Baht 193.07 million, an increase of 16.38% from the end of 2024. This was primarily driven by an increase in current liabilities, particularly construction payables of the subsidiary.

Non-current liabilities totaled Baht 51.33 million, increasing from the previous year due to higher provisions for employee benefit obligations.

### Shareholders' Equity

As of 31 December 2025, the Company's shareholders' equity amounted to Baht 1,715.43 million, representing a decrease of 2.66% from Baht 1,762.29 million at the end of 2024.

items	Consolidated financial statements (Unit: million Baht)		Change (percent)
	2025	2024	
Revenues from hospital operations	1,125.17	1,125.17	3.27%
Other income	24.43	24.43	5.36%
Cost of hospital operations	(751.44)	(751.44)	2.67%
Distribution costs	(10.23)	(10.23)	(9.78%)
Administrative expenses	(170.99)	(170.99)	2.60%
Finance costs	(0.57)	(0.57)	(10.53%)
Tax expense	(43.84)	(43.84)	10.99%
<b>Profit for the year</b>	<b>172.53</b>	<b>172.53</b>	<b>5.70%</b>

Further details and notes to the financial statements can be found in the 2025 Annual Report (Form 56-1 e-One Report), Section 3: Financial Statements.



## Performance Analysis

Based on the analysis of the Company's and its subsidiaries' operating results, net profit for the year 2025 amounted to Baht 182.37 million, representing an increase of 5.70% compared to the previous year. The key drivers were higher hospital revenue and increased revenue per visit for both Outpatient (OPD) and Inpatient (IPD) services, together with effective cost management. As a result, the Company was able to maintain a lower cost-to-revenue ratio, reflecting high-quality earnings growth.

For 2025, the Company recorded hospital operating costs of Baht 771.53 million, an increase of 2.67%, primarily due to higher costs of medicines and medical supplies, which vary in line with revenue. However, the ratio of hospital operating costs to hospital revenue decreased compared to the previous year, at 66.40% versus 66.78%, respectively, reflecting improved cost efficiency.

Selling and administrative expenses totaled Baht 184.67 million, increasing by 1.90% year-on-year, mainly due to higher personnel expenses and repair and maintenance costs. Nevertheless, the ratio of selling and administrative expenses to total revenue remained stable at 15.55%, compared to 15.76% in the previous year, demonstrating disciplined expense management.

In this regard, the Board of Directors deemed it appropriate to propose that the shareholders' meeting consider and approve the Company's financial statements for the year ended 31 December 2025.

The Chairman then inquired whether any shareholders or proxies had further questions. Shareholders were invited to submit questions via text or through the video call system.

The Meeting was given the opportunity to express opinions and raise questions regarding this agenda item; however, no shareholders raised any questions or comments. The Chairman then requested the Meeting to proceed with voting on this agenda item.

This agenda item required approval by a majority vote of the shareholders present and casting their votes.

**Resolution:** The Meeting resolved, by a majority vote of the shareholders present and voting, to approve the Company's financial statements for the year 2025, which had been audited by the external auditor, with the voting results as follows:

Resolution	Number of votes cast (1 share = 1 vote)	Calculated as a percentage of the number of shares attending the meeting and voting.
Approved	229,592,065	100.00
Disapproved	0	0.0000
Abstaining	0	shall not be included in the voting base
Voided ballot	0	0.0000

## Agenda 3 To approve the annual dividend payment for the year ended December 31, 2025

The Chairman assigned, Miss Supaporn Sukhee, Chief Financial Officer (CFO), to clarify the details related to this agenda for acknowledgement of the Meeting.

Ms. Supaporn Sukhee, Chief Financial Officer, reported that pursuant to Section 116 of the Public Limited Companies Act B.E. 2535 (1992) and Article 48 of the Company's Articles of Association, the Company is required to appropriate



at least 5% of its annual net profit, after deducting accumulated losses brought forward (if any), to a legal reserve until such reserve reaches not less than 10% of the registered capital.

Based on the Company's operating results, the Board of Directors has considered the provisions of the Public Limited Companies Act, the Company's Articles of Association, and the Company's performance, and noted that the Company recorded a net profit of Baht 185.80 million for the year ended 31 December 2025. As of 31 December 2025, the Company's legal reserve amounted to Baht 54.6 million, which has been fully appropriated, representing 10% of the paid-up registered capital.

The Board of Directors therefore deemed it appropriate to propose that the shareholders' meeting consider and approve the dividend payment. In making this proposal, the Board has taken into account the Company's operating results, financial position, and the interests of all stakeholders. As of the end of 2025, the Company has retained earnings available for distribution and has a dividend policy to pay dividends of not less than 40% of net profit after legal reserve. However, such dividend payments may vary depending on the Company's performance, expansion plans, liquidity, and other relevant factors as deemed appropriate by the Board.

Accordingly, the Board resolved to propose a dividend payment from the results of the second half of 2025 to shareholders of 546,000,000 shares, in cash at the rate of Baht 0.18 per share. This represents a dividend payout ratio of 51.39% of net profit based on the separate financial statements (calculated based on the number of shares entitled to dividends as of 31 December 2025, after deducting treasury shares), which is in line with the Company's dividend policy.

During 2025, the Company had already paid an interim dividend. The Board of Directors' Meeting No. 3/2025, held on 9 August 2025, approved an interim dividend for the first half of the year (accounting period from 1 January 2025 to 30 June 2025) at the rate of Baht 0.10 per share for 546,000,000 ordinary shares, totaling approximately Baht 53,040,700, which was paid on 9 September 2025.

As a result, the total dividend payment for the year 2025 amounted to Baht 0.28 per share, totaling approximately Baht 185,796,786, or 79.93% of the Company's net profit for 2025, which is consistent with the Company's dividend policy.

**Details of the dividend payments for the years 2023–2025 are as follows:**

Description	2023	2024	2025
Net Profit (Million Baht)	184.49	172.53	185.80
Total Dividend Paid (Million Baht)	163.80	158.12*	148.51
Interim Dividend Paid (Million Baht)	60.06	60.06	53.04
Annual Dividend Paid (Million Baht)	103.74	98.06*	95.47
Dividend Payout Ratio (% of Net Profit)	88.79	91.57	79.93

\* The Company has implemented a share repurchase program for financial management purposes, with the program running from December 13, 2024, to June 12, 2025. As of December 31, 2024, the Company had repurchased a total of 1,247,000 shares.

The Company has implemented a share repurchase program for financial management purposes during the period from 13 December 2024 to 12 June 2025. As of 31 December 2025, the Company had repurchased a total of 16,611,400 shares.



Individual shareholders are entitled to claim a dividend tax credit in accordance with Section 47 bis of the Revenue Code. The dividend of Baht 0.18 per share is paid from net profit subject to corporate income tax at the rate of 20%. Accordingly, shareholders are entitled to a tax credit at the rate of 20/80 of the dividend received.

Subject to shareholders' approval of the dividend payment at this Meeting, the Company has set the Record Date for shareholders entitled to receive dividends as 30 April 2026, and the Payment Date for cash dividends as 19 May 2026.

The Chairman then invited shareholders to ask questions and express opinions via video conference or by submitting questions through the IR Plus system. A shareholder submitted the following question:

**Question:** Mr. Delong Maximilian Hin, a shareholder attending the Meeting online in person, inquired about the Company's plan regarding the treasury shares repurchased.

**Answer:** Dr. Teerawat Srinakarin, Director and Chief Executive Officer, responded that the Board of Directors has not yet resolved on the course of action regarding the treasury shares. The Company will carefully consider all relevant factors, including market conditions and share price at the time when action is required under applicable regulations, before making a decision.

If market conditions are not favorable, the Company may consider retaining the shares, with due regard to the best interests of the Company and its shareholders.

The Chairman then invited further questions or comments from the Meeting.

No additional questions or comments were raised. The Chairman then requested the Meeting to proceed with voting on this agenda item.

This agenda item required approval by a majority vote of the shareholders present and entitled to vote.

**Resolution:** The Meeting resolved, by a majority vote of the shareholders present and voting, to approve the dividend payment for the operating results for the year ended 31 December 2024 as proposed by the Board of Directors, with the voting results as follows:

Resolution	Number of votes cast (1 share = 1 vote)	Calculated as a percentage of the number of shares attending the meeting and voting.
Approved	229,592,065	100.00
Disapproved	0	0.0000
Abstaining	0	shall not be included in the voting base
Voided ballot	0	0.0000

#### Agenda 4 To approve the election of directors to replace the directors retiring by rotation for year 2026.

The Chairman assigned Ms. Chularat Sirisingh, Company Secretary, to report to the Meeting.

Ms. Chularat Sirisingh reported that, pursuant to Section 71 of the Public Limited Companies Act B.E. 2535 (1992) (as amended) and the Company's Articles of Association, directors are required to retire by rotation at each Annual General Meeting at a rate of one-third of the total number of directors.

At present, the Company has a total of 10 directors. At the 2026 Annual General Meeting, three directors are due to retire by rotation, namely:



1. Dr. Teerawat Srinakarin – Director and Chief Executive Officer
2. Associate Professor Dr. Srichai Krusanthi – Director
3. Mr. Vorathep Rangchaikul – Independent Director and Audit Committee Member

The Company had provided shareholders with the opportunity to propose agenda items and nominate candidates for directorship during the period from 1 October to 31 December 2025, through the electronic system of the Stock Exchange of Thailand and the Company’s website. No shareholder proposed any agenda or nominated any candidate for consideration.

The Board of Directors (excluding interested directors) has carefully considered and screened the nominated individuals in accordance with the Company’s selection process. The Board is of the opinion that the nominated persons possess the required qualifications, are suitable for the Company’s business, and have expertise aligned with the Board Skills Matrix. The Board also considered that the nominee for independent director meets all qualifications required under the relevant laws and regulations.

Therefore, the Board deemed it appropriate to propose to the Annual General Meeting for approval to re-elect the three directors retiring by rotation to serve another term as follows:

1. Dr. Teerawat Srinakarin – Director and Chief Executive Officer
2. Associate Professor Dr. Srichai Krusun – Director
3. Mr. Vorathep Rangchaikul – Independent Director and Audit Committee Member

#### **Board’s Consideration**

The Board of Directors (excluding interested directors) carefully evaluated the qualifications of all three nominees, taking into account their knowledge, capabilities, diverse experience (Board Skills Matrix), past performance as directors, and personal qualifications in line with the Company’s business strategy. The Board’s opinions are summarized as follows:

- Two incumbent directors: Demonstrated strong performance and possess in-depth understanding of the Company’s medical business (details as shown in **Attachment 2 of the Notice of the Meeting**).
- Independent Director (Mr. Vorathep Rangchaikul): The Board considers that he possesses all qualifications required by law and is capable of providing independent opinions.

#### **Additional Disclosure (Conflict of Interest)**

Mr.Vorathep Rangchaikul, as an independent director, also serves as an advisor to the Chief Executive Officer of another hospital, which may be considered a potentially competing business of a listed hospital.

The Board has carefully considered that such hospital operates in a different geographic area and is not a direct competitor of the Company. Therefore, the Board is of the opinion that such position does not affect his ability to perform his duties or to provide independent opinions as a director of the Company. The Company will disclose this information to the shareholders’ meeting for transparency. Upon reviewing his independence qualifications, the Board concluded that Mr.Vorathep Rangchaikul, fully complies with the Public Limited Companies Act and does not possess any prohibited characteristics under the Securities and Exchange Act and the regulations of the Securities and Exchange Commission. He meets all criteria for an independent director as defined in **Attachment 3**.



The Meeting was then invited to express opinions and ask questions regarding this agenda item. No questions or comments were raised.

The Moderator informed the Meeting that this agenda item required approval by a majority vote of the shareholders present and voting, and that voting would be conducted on an individual basis for each director.

Shareholders and proxies were then invited to cast their votes via the IR Plus AGM application within one minute, voting for each director individually.

**Resolution:** The Meeting resolved, by a majority vote of the shareholders present and entitled to vote, to re-elect Dr. Teerawat Srinakarin, Associate Professor Dr. Srichai Krusun, and Mr. Vorathep Rangchaikul as directors for another term, as proposed in all respects, with voting results on an individual basis as follows:

#### 4.1 Dr. Teerawat Srinakarin

Resolution	Number of votes cast (1 share = 1 vote)	Calculated as a percentage of the number of shares attending the meeting and voting.
Approved	229,592,065	100.00
Disapproved	0	0.0000
Abstaining	0	shall not be included in the voting base
Voided ballot	0	0.0000

#### 4.2 Associate Professor Dr. Srichai Krusun

Resolution	Number of votes cast (1 share = 1 vote)	Calculated as a percentage of the number of shares attending the meeting and voting.
Approved	229,592,065	100.00
Disapproved	0	0.0000
Abstaining	0	shall not be included in the voting base
Voided ballot	0	0.0000

#### 4.3 Mr. Vorathep Rangchaikul

Resolution	Number of votes cast (1 share = 1 vote)	Calculated as a percentage of the number of shares attending the meeting and voting.
Approved	229,592,065	100.00
Disapproved	0	0.0000
Abstaining	0	shall not be included in the voting base
Voided ballot	0	0.0000

### Agenda 5 Consider approving the remuneration of the Company's directors and sub-committees for 2026

The Chairman assigned Associate Professor Dr. Srichai Krusun the Board of director, to present the report for this agenda item.

Associate Professor Dr. Srichai Krusun reported that, in accordance with Section 90 of the Public Limited Companies Act B.E. 2535 (1992), which stipulates that director remuneration must be approved by the shareholders' meeting,



and Article 22 of the Company's Articles of Association, which specifies that directors are entitled to receive remuneration in the form of rewards, meeting allowances, gratuities, bonuses, or other benefits as determined by the Articles of Association or by resolution of the shareholders' meeting, the Company has formulated a director remuneration policy. This policy considers the appropriateness relative to the assigned duties and responsibilities and is benchmarked against companies listed on the Stock Exchange of Thailand within similar industries and of comparable size.

The Company has established a policy to determine directors' remuneration in an appropriate, fair, and transparent manner, taking into account the scope of duties, responsibilities, and roles of each director, as well as their experience, knowledge, capabilities, time commitment, and the benefits expected to be derived by the Company. This is to ensure that the level of remuneration is sufficient to attract and retain qualified directors and is comparable to that of listed companies of similar size and industry. Such approach is consistent with the guidelines supported by the Thai Institute of Directors (IOD), which emphasize clear disclosure of directors' responsibilities and remuneration components.

The Board of Directors has considered the directors' remuneration for the year 2026 in accordance with the Company's remuneration policy, taking into account benchmarking data from comparable listed companies and industry peers, as well as relevant directors' remuneration surveys. The consideration also included the Company's performance, overall economic conditions, and the appropriateness of duties and responsibilities of both the Board and its sub-committees. This is to ensure that the remuneration determination process is prudent, transparent, and verifiable, in line with good corporate governance principles.

The Board therefore deemed it appropriate to propose to the shareholders' meeting for approval the remuneration of the Board of Directors and sub-committees for the year 2026, in the form of monthly remuneration and meeting allowances, excluding bonuses, within a total limit not exceeding Baht 3,500,000 per year, which is the same ceiling as approved for the year 2025.

For clarity, transparency, and compliance with good corporate governance principles, the Company will disclose the remuneration components, criteria for consideration, approved limits, and actual payments in the 56-1 One Report and the shareholders' meeting documents, enabling shareholders to make informed decisions.

For details of the remuneration of the Board of Directors and sub-committees for the year 2026, I would like to invite the Company Secretary to present further details to the Meeting.

For further details regarding the proposed remuneration for directors and sub-committees for 2025, the Company Secretary has been assigned to provide additional explanations.



## 1. Monetary Remuneration

### (1) Meeting Allowances and Monthly Remuneration

Position	Meeting Allowance (Baht per meeting) (Only for directors attending the meeting)		Remuneration (Baht per month) (Calculated based on the duration of the position held)	
	Year 2025	Year 2025 (Proposed) <i>(increase from 2025)</i>	Year 2025	Year 2026 (Proposed) <i>(same as 2025)</i>
<b>Board of Director</b>				
Chairman of the Board	14,400	18,000	15,000	15,000
Member of the Board	12,000	15,000	15,000	15,000
<b>Audit Committee</b>				
Chairman of the Audit Committee	14,400	18,000	None	None
Member of the Audit Committee	12,000	15,000	None	None
<b>Risk Management Committee</b>				
Chairman of the Risk Management Committee	14,400	18,000	None	None
Member of the Risk Management Committee	12,000	15,000	None	None

### (2) Bonus (Year 2025)

Bonus	Year 2025	(Year 2026 — Proposed)
<i>(Not included in the directors' remuneration framework)</i>	Directors will receive a bonus of 2% of the total dividend paid, not exceeding 1,800,000 Baht.	Directors will receive a bonus of 2% of the total dividend paid, not exceeding 1,800,000 Baht. (same as in 2025). <i>The proposed bonus amount will not be included in the directors' remuneration framework. The Board of Directors shall have the discretion to determine the allocation, methods, and conditions of the bonus distribution.</i>

For the previous year, the Company paid total directors' remuneration in the amount of approximately Baht 2,620,200, which was within the limit approved by the shareholders' meeting for the year 2025.

Details are disclosed in the 2025 Annual Registration Statement (Form 56-1 e-One Report) under the section "Corporate Governance Structure," sub-section "Directors' Remuneration."

## 2. Non-monetary and/or Other Benefits

Description	Year 2025	Year 2026 (Proposed)	Change
Medical care and annual health check-up for directors and their families	300,000 Baht/person/year	300,000 Baht/person/year	No change from 2025

Details of the payment of monetary compensation to directors for the year 2025 are as shown in 56-1 e-One Report, pages 227-228.



Therefore, the Board of Directors deemed it appropriate to propose to the 2026 Annual General Meeting of Shareholders for consideration and approval the remuneration of the Board of Directors and all sub-committees for the year 2026, excluding annual bonuses, within a total limit not exceeding Baht 3,500,000 per year, which is the same ceiling as approved for the year 2025.

In this regard, during 2025, the Company paid annual bonuses to the Board of Directors in accordance with the criteria approved by the shareholders. The allocation and distribution of such bonuses were determined by the Board based on appropriateness.

The remuneration of the Board of Directors and sub-committees shall be effective from the date of approval by the shareholders' meeting until otherwise resolved by the shareholders' meeting.

The Moderator then invited shareholders to ask questions and express opinions by submitting questions through the IR Plus AGM system or via video conference. The Moderator also presented relevant details and the rationale for the proposed adjustment of meeting allowances for the Board and all sub-committees.

After the allotted time for questions had elapsed, no questions were raised.

The Vice Chairman then proposed that the Meeting consider and approve the remuneration of the Board of Directors and all sub-committees for the year 2026 as detailed above. This agenda item required approval by not less than two-thirds of the total votes of the shareholders present at the Meeting.

**Resolution:** The Meeting resolved to approve the remuneration of the Board of Directors and all sub-committees for the year 2026 as proposed by the Board, with a vote of not less than two-thirds of the total votes of the shareholders present, with the voting results as follows:

Resolution	Number of votes cast (1 share = 1 vote)	Calculated as a percentage of the number of shares attending the meeting and voting.
Approved	229,592,065	100.00
Disapproved	0	0.0000
Abstaining	0	shall not be included in the voting base
Voided ballot	0	0.0000

#### **Agenda 6 To consider and approve the Appointment of Auditors and Determination the Audit Fee for the year 2026**

The Chairman assigned Mr. Viroj Jindamaneepitak, Chairman of the Audit Committee, to present details regarding the appointment of the auditor and determination of the audit fee for the year 2026.

Mr. Viroj Jindamaneepitak reported that, in accordance with Section 120 of the Public Limited Companies Act B.E. 2535 (1992) and Article 39 of the Company's Articles of Association, the Annual General Meeting of Shareholders is required to appoint the auditor and determine the audit fee of the Company on an annual basis.

For the year 2026, the Audit Committee has carefully considered and selected the auditor by taking into account independence, qualifications, knowledge, capabilities, experience, expertise in auditing listed companies, as well as the appropriateness of the audit fee. As the Company has continuously engaged PV Audit Co., Ltd. as its auditor since 2018, the Audit Committee considered it appropriate to select a new audit firm to provide fresh perspectives



and recommendations from an external auditor, which would be beneficial to the Company's corporate governance and financial review, and in line with good corporate governance principles.

After due consideration, the Audit Committee deemed it appropriate to propose the appointment of KPMG Phoomchai Audit Ltd. ("KPMG") as the Company's auditor for the year 2026. This is the first year of proposed appointment, as KPMG is an independent audit firm with strong qualifications, knowledge, experience, and expertise in auditing companies listed on the Stock Exchange of Thailand, and offers an appropriate audit fee.

#### **Board of Directors' Resolution:**

The Board of Directors approved the Audit Committee's proposal to appoint KPMG Phoomchai Audit Ltd.. as the Company's auditor for the year 2026 and resolved to propose this appointment to the 2026 Annual General Meeting of Shareholders for approval.

#### **1) To consider and approve the appointment of the Company's auditors for the year 2026, as follows:**

	Names of Auditors	Certified Public Accountant No.	Years of Auditing the Company's Financial Statements
1	Ms. Wilaiwan Polprasert	8420	Has never signed the Company's financial statements.
2	Ms. Nawarat Nitikeatipong	7789	Has never signed the Company's financial statements.
3	Mr. Songchai Wongpiriyaporn	10996	Has never signed the Company's financial statements.

Any one of the licensed auditors listed above shall be authorized to audit and express an opinion on the Company's consolidated financial statements and separate financial statements for the year 2026. In the event that any of the said auditors is unable to perform his/her duties, another licensed auditor from the same audit firm, with qualifications in accordance with applicable laws, may be appointed to perform such duties in replacement.

All three proposed auditors possess qualifications in accordance with the requirements of the Securities and Exchange Commission (SEC), are independent, and have expertise in auditing. None of the proposed auditors are shareholders of the Company, have any relationship with the Company, or have any interest in the Company, its subsidiaries, management, major shareholders, or related persons. They have not provided consultancy services to the Company and are therefore independent in performing their duties and expressing opinions on the Company's financial statements. Details of their profiles are provided in Attachment 4 of the Notice of the Meeting.

#### **2) Approval of the Audit Fee for the Year 2026**

The proposed audit fee for the year 2026 is Baht 1,650,000, with no non-audit fees. Expenses related to audit work, such as travel, accommodation, meals, document preparation and copying, and office supplies, will be charged separately by the audit firm.

#### **3) Acknowledgment of the Audit Fee for Subsidiaries for the Year 2026**

KPMG Phoomchai Audit Ltd. has also been selected as the auditor of the Company's subsidiaries for the year 2026, with an audit fee of Baht 175,000.

The Board of Directors will oversee the preparation and review of the financial statements of the Company and its subsidiaries to ensure that they are accurate, complete, transparent, and completed within the timeframe



prescribed by law and regulatory authorities. This is to ensure consistency in financial reporting across the group, enhance reliability, and provide benefits to shareholders and all stakeholders.

Thereafter, Professor Vallop Laopaiboon, Vice Chairman of the Board, invited the Meeting to express opinions and ask questions regarding this agenda item. No questions or comments were raised.

The Meeting was then requested to proceed with voting on this agenda item.

**Resolution:** The Meeting resolved unanimously to approve the appointment of the auditors and the determination of the audit fee for the year 2026 as proposed in all respects, with the voting results as follows:

Resolution	Number of votes cast (1 share = 1 vote)	Calculated as a percentage of the number of shares attending the meeting and voting.
Approved	229,516,075	100.00
Disapproved	0	0.0000
Abstaining	75,990	shall not be included in the voting base
Voided ballot	0	0.0000

#### Agenda 7: Consideration of Other Matters (if any)

No shareholders proposed any additional matters for consideration.

Professor Vallop Laopaiboon, Vice Chairman of the Board, addressed the Meeting that this agenda item was designated to provide shareholders with an opportunity to raise questions or provide additional comments. However, for the sake of transparency and to ensure equal rights for all shareholders, no additional agenda items should be introduced beyond those specified in the Notice of the Meeting, as shareholders have already reviewed the information, submitted proxies, and, in some cases, cast their votes.

Furthermore, the Company has complied with good corporate governance principles of the Stock Exchange of Thailand by providing shareholders with the opportunity to propose agenda items in advance during the period from 1 October to 31 December 2025, and to submit questions in advance between 1–21 April 2026. Such information was duly disclosed via the SET information system and the Company's website.

Accordingly, no voting would be conducted under this agenda item. Shareholders were invited to ask questions, express opinions, or provide suggestions by submitting questions through the available channels, either via text or video call, and to state their full name prior to asking questions for record-keeping purposes.

#### Question & Answer Session

**Question:** Ms. Nattha Somjaivong, a shareholder attending the Meeting online in person, inquired about the Company's competitive strategy, including its strengths and advantages compared to other hospitals, as well as those of Ratchaphruek Hospital and Ratchaphruek-Kaenphanga Hospital.

**Answer:** Dr. Teerawat Srinakarin, Director and Chief Executive Officer, explained that the Company places strong emphasis on competition in the hospital business by building confidence among both existing and new patients through development in two key areas:



1. Medical Quality

The Company continuously enhances its capabilities in treatment, including specialist physicians, medical technology, diagnostics, and treatment of more complex diseases, as well as investments in new technologies to improve both treatment quality and disease prevention.

2. Patient Experience

The Company focuses on improving services under the concept of Humanized Person-Centered Care, emphasizing safety, trust, and positive experiences for patients and their families, while ensuring seamless service processes before, during, and after treatment.

In addition, the Company values patient feedback to continuously improve service quality and leverages information technology to enhance service efficiency.

As for its strengths, the Company benefits from a strong combination of high-quality medical care, service standards, and accessible pricing relative to premium healthcare standards, which enhances competitiveness and builds patient trust.

Regarding Ratchaphruek–Kaenphanga Hospital, the Company has defined its growth strategy based on three core principles: Beauty, Truth, and Goodness, focusing on aesthetic and plastic surgery services under medical standards, professional ethics, and the concept of Accessible Premium, aiming to differentiate itself and achieve sustainable growth.

**Question:** Mr.Kritchakorn Marwiang, a shareholder attending the Meeting online in person, asked whether the current geopolitical conflict situation would have any impact on the Company.

**Answer:** Dr.Teerawat Srinakarin responded that the Company closely monitors such situations, as they may affect the economy, energy costs, and patient behavior, particularly decisions regarding healthcare spending and travel for treatment.

However, many medical services remain essential and require diagnosis and treatment. For aesthetic services at Ratchaphruek–Kaenphanga Hospital, the Company has a clearly defined target group. Therefore, the Company continues to focus on maintaining confidence in quality, standards, and safety to sustain competitiveness and support future growth.

The Chairman then asked whether there were any further questions.

No additional questions were raised by any shareholders or proxies.

The Moderator informed the Meeting that, following the conclusion of the 2026 Annual General Meeting, the Company will publish the minutes of the Meeting in both Thai and English, along with a summary of questions and answers, on the Company’s website and through the SET information disclosure system within 14 days. Shareholders may submit any inquiries or comments to the Company Secretary within one month from the date of the Meeting.



บริษัท โรงพยาบาลราชพฤกษ์ จำกัด (มหาชน)

456 หมู่ 14 ถนนมิตรภาพ ตำบลในเมือง อำเภอเมืองขอนแก่น จังหวัดขอนแก่น ไปรษณีย์ 40000  
อีเมล : info@rph.co.th โทร 043 333 555 เว็บไซต์ : https://rph.co.th

**RATCHAPHRUEK HOSPITAL PUBLIC COMPANY LIMITED**

456 Moo 14 Mittrparb Road Nai-Mueang Mueang Khon Kaen Postcode 40000  
E-mail : info@rph.co.th Tel. 043 333 555 Website : https://rph.co.th


Minutes of the 2026 Annual General Meeting of Shareholders Page 22/19

Finally, the Chairman, on behalf of the Board of Directors and the management team, expressed appreciation to all shareholders for their continued support of the Company's operations and for attending the Meeting.

The meeting was adjourned at 15:00 p.m.



Signed  Chairman of the Meeting  
(Mr. Sudhon Sriyapant)  
Chairman of the Board

Signed  Minute taker  
(Miss Chularat Sirisingh)  
Company Secretary

*Note: During the meeting, the Company recorded video footage for purposes related to the shareholders' meeting, in accordance with the Company's Privacy Policy. Prior to the commencement of the meeting, the moderator informed shareholders and proxy holders of this policy.*